<DOC>
	<DOCNO>NCT02115750</DOCNO>
	<brief_summary>This two part study compare CHS-0214 Enbrel patient active rheumatoid arthritis inadequate response Methotrexate ( MTX ) naive biologic therapy . Pt.1 24-week randomize , double-blind , active-control , parallel-group , multi-center global study . The primary end point 20 % improvement American College Rheumatology criterion ( ACR-20 ) week 24 . Comparing CHS-0214 Enbrel efficacy safety . Pt . 2 open-label single arm study patient least ACR-20 response receive CHS-0214 . Continued response safety evaluate .</brief_summary>
	<brief_title>Comparison CHS-0214 Enbrel ( Etanercept ) Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male female adult RA diagnosis 6 month On stable dose MTX 8mg 25mg per week Active disease : great 6 tender joint , great 6 swollen joint , Creactive protein ( CRP ) great equal 0.5mg/dL , disease activity score ( DAS ) 28 joint ( DAS28CRP ( 4 ) ) great equal 3.2 Use prednisone great 10mg/day Use great one nonsteroidal antiinflammatory drug ( NSAID ) Use biologic therapy cause Chemistry hematology value outside protocol specify range Positive QuantiFERONtuberculosis ( TB ) Gold Test Evidence active lung disease chest xray Major systemic infection Presence significant comorbid condition Known allergy latex Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CHS-0214</keyword>
	<keyword>Enbrel</keyword>
	<keyword>RA</keyword>
	<keyword>Biosimilar</keyword>
	<keyword>Etanercept</keyword>
</DOC>